OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Barinthus Biotherapeutics OCF Yield % Related Terms
Barinthus Biotherapeutics OCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Barinthus Biotherapeutics's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Barinthus Biotherapeutics OCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Barinthus Biotherapeutics's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Barinthus Biotherapeutics's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Barinthus Biotherapeutics (BRNS) has a OCF Yield % of -143.87 as of Jul. 05, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Barinthus Biotherapeutics and its competitors. According to the industry distribution chart, Barinthus Biotherapeutics ranks #1317 out of 1410 companies in the Biotechnology industry, placing it in the top 93.4%.
Is Barinthus Biotherapeutics' OCF Yield % too high?
Barinthus Biotherapeutics' current OCF Yield % is -143.87. Based on the distribution chart, Barinthus Biotherapeutics ranks #1317 out of 1410 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Barinthus Biotherapeutics has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Barinthus Biotherapeutics' OCF Yield % compare to VTGN and PSTV?
According to the Biotechnology industry distribution chart, Barinthus Biotherapeutics ranks #1317 out of 1410 companies for OCF Yield %. This places Barinthus Biotherapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Barinthus Biotherapeutics and its competitors. Barinthus Biotherapeutics's current OCF Yield % is -143.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Barinthus Biotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Barinthus Biotherapeutics (BRNS) is currently considered Possible Value Trap. The stock's GF Value™ is $1.12, compared to a current price of $0.62 — trading 44.6% below its estimated fair value. The current OCF Yield % is -143.87. Barinthus Biotherapeutics' overall GF Score™ is 52/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Barinthus Biotherapeutics (BRNS), the current OCF Yield % is -143.87 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Barinthus Biotherapeutics (BRNS) Overvalued in 2026?
Based on GuruFocus' analysis, Barinthus Biotherapeutics stock appears to be undervalued.
The current stock price of $0.62 is trading 44.6% below its estimated GF Value™ of $1.12.
GuruFocus considers Barinthus Biotherapeutics to be Possible Value Trap.
Key valuation signals for BRNS:
OCF Yield %: -143.87
GF Value™: $1.12 vs. price of $0.62 (44.6% below fair value)
No single metric tells the full story. See the BRNS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.
52GF Score
Get the complete analysis for BRNS
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BRNS has been successfully added to your 
